Lung Cancer Clinical Trials in Iowa City, Iowa

4 studies are recruiting for lung cancer in Iowa City, Iowa right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Local Institution - 0065, Iowa City, Iowa
    Locations
    65 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT06618287 on ClinicalTrials.gov

  2. CHAMP Lung Cancer Screening Program

    The U.S. Preventive Services Task Force recommends annual lung cancer screening (LCS) with low-dose CT for adults aged 50-80 with a ≥20 pack-year smoking history who currently smoke or quit within the past 15 years. Despite insurance coverage, only 17% of eligible Iowans were screened in 2024. Barr…

    Stage
    Not phased
    Ages
    50 to 77
    Site
    University of Iowa, Iowa City, Iowa
    Locations
    3 in total
    Run by
    Jill Kolesar

    See if you can join NCT07572773 on ClinicalTrials.gov

  3. Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

    TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Iowa Health Care, Iowa City, Iowa
    Locations
    18 in total
    Run by
    Tango Therapeutics, Inc.

    See if you can join NCT06922591 on ClinicalTrials.gov

  4. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Iowa Hospital and Clinics, Iowa City, Iowa
    Locations
    39 in total
    Run by
    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.